Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.

Abstract excerpt

Mutations in the RAS-RAF-MEK-ERK pathway are frequent alterations in cancer and RASopathies, and while RAS oncogene activation alone affects 19% of all patients and accounts for approximately 3.4 million new cases every year, less frequent alterations in the cascade's downstream effectors are also involved in cancer etiology. RAS proteins initiate the signaling cascade by promoting the dimerization of RAF...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Molecular Targeted Therapy
• Share to Mutation